The dashes (--) indicate doses that would exceed a standard 100-unit insulin syringe capacity at that concentration
It is important to distinguish between a direct pharmacological effect and secondary symptoms arising from altered eating patterns or digestive function
Talk with your care team before starting, stopping, or changing any medication
Secondary outcomes include change in waist circumference, change in BMI, change in percent body fat, change in visceral and subcutaneous adipose tissue, change in trunk fat mass, percentage of weight loss due to fat mass or lean mass, quality of life, and more
The medication's absorption occurs before bile plays any significant role in digestion, and the systemic effects of semaglutide are not dependent on bile-mediated fat absorption